Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
Open Access
- 8 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 38 (20) , 7100-7111
Abstract
The potency and specificity of locked nucleic acid (LNA) antisense oligonucleotides was investigated as a function of length and affinity. The oligonucleotides were designed to target apolipoprotein B (apoB) and were investigated both in vitro and in vivo. The high affinity of LNA enabled the design of short antisense oligonucleotides (12- to 13-mers) that possessed high affinity and increased potency both in vitro and in vivo compared to longer oligonucleotides. The short LNA oligonucleotides were more target specific, and they exhibited the same biodistribution and tissue half-life as longer oligonucleotides. Pharmacology studies in both mice and non-human primates were conducted with a 13-mer LNA oligonucleotide against apoB, and the data showed that repeated dosing of the 13-mer at 1–2 mg/kg/week was sufficient to provide a significant and long lasting lowering of non-high-density lipoprotein (non-HDL) cholesterol without increasing serum liver toxicity markers. The data presented here show that oligonucleotide length as a parameter needs to be considered in the design of antisense oligonucleotide and that potent short oligonucleotides with sufficient target affinity can be generated using the LNA chemistry. Conclusively, we present a 13-mer LNA oligonucleotide with therapeutic potential that produce beneficial cholesterol lowering effect in non-human primates.Keywords
This publication has 36 references indexed in Scilit:
- Expression of Apolipoprotein B in the Kidney Attenuates Renal Lipid AccumulationJournal of Biological Chemistry, 2010
- Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagentsNucleic Acids Research, 2009
- Locked Nucleic Acid: Properties and Therapeutic Aspects2008
- Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animalsNucleic Acids Research, 2006
- Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302)Oligonucleotides, 2006
- Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV‐1 genome dimerization and inhibit virus replicationFEBS Letters, 2004
- A Functionally Improved Locked Nucleic Acid Antisense Oligonucleotide Inhibits Bcl-2 and Bcl-xL Expression and Facilitates Tumor Cell ApoptosisOligonucleotides, 2004
- A Functionally Improved Locked Nucleic Acid Antisense Oligonucleotide Inhibits Bcl-2 and Bcl-xL Expression and Facilitates Tumor Cell ApoptosisOligonucleotides, 2004
- Rapid Screening Method for Antisense Oligonucleotides Against Human Growth Factor Receptor p185 erbB-2Oligonucleotides, 2004
- Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosisJournal of Lipid Research, 2003